Incidence of Low Seroimmunity to Hepatitis B Virus in Children With Inflammatory Bowel Disease

Watts, Abhishek; Bennett, William E.; Molleston, Jean P.; Gupta, Sandeep K.; Croffie, Joseph M.; Waseem, Shamaila; McFerron, Brian A.; Steiner, Steven J.; Kumar, Sanjay; Vanderpool, Charles; Hon, Emily; Bozic, Molly; Subbarao, Girish; Pfefferkorn, Marian D.

doi:10.1097/mpg.0000000000001580

Cited by 19 publications

(32 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Second, the dose of hepatitis B vaccine varies in pediatric studies. Urganci et al [12] administered 20 µg hepatitis B vaccine, while three other studies, including ours, used a 10-µg dose [10,11]. In all studies, full HBV vaccination was defined as 3 doses; however, in a study by Moses et al, "three or more doses" were considered as the full series [11].…”

Section: Discussionmentioning

confidence: 95%

“…First, we measured the antibody level approximately 14 years after vaccination. In the Urganci et al study [12], the period after vaccination was 4 weeks, and the time was not reported in studies by Watts et al [10] and Moses et al [11]. It is documented that in immunocompetent individuals who are fully vaccinated against HBV, protective serologic titers may persist for more than 20 years, and no booster dose is recommended [15].…”

Section: Discussionmentioning

confidence: 99%

“…Data on the immunogenicity of hepatitis B vaccine in pediatric patients with IBD are limited. The results of previous studies reported that between 28% and 70.2% of children with IBD are seroprotected against HBV infection [10,11]. However, many differences in the methodologies of these studies hamper the comparison of the results.…”

Section: Discussionmentioning

confidence: 99%

“…To date, based on the results of a meta-analysis by Jiang et al, the immunogenicity of hepatitis B vaccine in adult patients with IBD was determined to be 61% [9]. In children with IBD, in a small number of studies, immunity to hepatitis B varied from 28% to 70.2% [10][11][12], but the children were not vaccinated during infancy in any of these studies.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Immune response to hepatitis B vaccination in pediatric patients with inflammatory bowel disease

Baranowska-Nowak¹,

Iwańczak

Szczepanik

et al. 2020

cejoi

View full text Add to dashboard Cite

Aim of the study: to evaluate the immune response rate in children with inflammatory bowel disease (IBD) who received the full hepatitis B vaccination course in infancy. we also evaluated rates of response to booster doses. Material and methods: participants were 1-to 18-year-old children with IBD, who received 3 doses of the hepatitis B vaccine in infancy. the study subjects were on no immunosuppressive therapy, on immunomodulators, on biological therapy, or received combo therapy. anti-hepatitis B surface antibody (anti-hBs) level ≥ 10 mIu/ml was considered to be seroprotective. patients with anti-hBs level < 10 mIu/ml received 1 or 3 doses of hepatitis B vaccine, and their post-vaccination anti-hBs levels were evaluated. Results: In total, we included 157 subjects, with a median age of 14.5 years. anti-hBs levels ≥ 10 miu/ml were found in 84/157 (53.5%) patients and were not associated with age (p = 0.3), sex (p = 0.7), or IBD type (p = 0.9). there was no significant difference in the rate of seroconversion between IBD patients treated with no immunosuppressive drugs, immunomodulators, biologicals, and combo therapy (30.4% vs. 39.3% vs. 2.7% vs. 7.1%, respectively, p = 0.3). after the first and third dose of booster vaccine, anti-hBs levels ≥ 10 mIu/ml were as follows: 92% and 100%, respectively. Conclusions: the immune response in children with IBD, who received the full series of hepatitis B vaccinations in infancy was inadequate and did not depend on the type of therapy. the booster dose(s) of vaccine could help to protect this group of patients from hepatitis B virus.

show abstract

Section: Discussionmentioning

confidence: 95%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Immune response to hepatitis B vaccination in pediatric patients with inflammatory bowel disease

Baranowska-Nowak¹,

Iwańczak

Szczepanik

et al. 2020

cejoi

View full text Add to dashboard Cite

show abstract

“…For instance, it has been reported that 6-TG can combat Middle East respiratory syndrome coronavirus infection by augmenting interferon responses (Cheng et al, 2015) and it has also reported that Simian virus 40 DNA replication is antagonized by 6-TG (Maybaum et al, 1987). Interestingly, it was reported that vaccinated IBD patients had lower titers of hepatitis B surface antibody (HBsAb), which might be influenced by the use of immunosuppressants including 6-TG (Watts et al, 2017).…”

Section: Discussionmentioning

confidence: 99%

6-Thioguanine inhibits rotavirus replication through suppression of Rac1 GDP/GTP cycling

et al. 2018

View full text Add to dashboard Cite

Rotavirus infection has emerged as an important cause of complications in organ transplantation recipients and might play a role in the pathogenesis of inflammatory bowel disease (IBD). 6-Thioguanine (6-TG) has been widely used as an immunosuppressive drug for organ recipients and treatment of IBD in the clinic. This study aims to investigate the effects and mode-of-action of 6-TG on rotavirus replication. Human intestinal Caco2 cell line, 3D model of human primary intestinal organoids, laboratory rotavirus strain (SA11) and patient-derived rotavirus isolates were used. We have demonstrated that 6-TG significantly inhibits rotavirus replication in these intestinal epithelium models. Importantly, gene knockdown or knockout of Rac1, the cellular target of 6-TG, significantly inhibited rotavirus replication, indicating the supportive role of Rac1 for rotavirus infection. We have further demonstrated that 6-TG can effectively inhibit the active form of Rac1 (GTP-Rac1), which essentially mediates the anti-rotavirus effect of 6-TG. Consistently, ectopic over-expression of GTP-Rac1 facilitates but an inactive Rac1 (N17) or a specific Rac1 inhibitor (NSC23766) inhibits rotavirus replication. In conclusion, we have identified 6-TG as an effective inhibitor of rotavirus replication via the inhibition of Rac1 activation. Thus, for transplantation patients or IBD patients infected with rotavirus or at risk of rotavirus infection, the choice of 6-TG as a treatment appears rational.

show abstract

High Rates of Seroprotection to Hepatitis B After a Hepatitis B Challenge Dose in Previously Vaccinated Patients with Inflammatory Bowel Disease on Immunosuppressive Therapy

Ley,

Lazarus,

Forati

et al. 2024

Dig Dis Sci

View full text Add to dashboard Cite

Incidence of Low Seroimmunity to Hepatitis B Virus in Children With Inflammatory Bowel Disease

Abstract: Nearly two-thirds of pediatric patients with IBD have low titers against hepatitis B virus. Titers were highest in the younger patients. No patient-specific variable, such as the use of immunosuppressants, appeared to influence these low titers.

Cited by 19 publications

References 37 publications

Immune response to hepatitis B vaccination in pediatric patients with inflammatory bowel disease

Immune response to hepatitis B vaccination in pediatric patients with inflammatory bowel disease

6-Thioguanine inhibits rotavirus replication through suppression of Rac1 GDP/GTP cycling

High Rates of Seroprotection to Hepatitis B After a Hepatitis B Challenge Dose in Previously Vaccinated Patients with Inflammatory Bowel Disease on Immunosuppressive Therapy

Contact Info

Product

Resources

About